Literature DB >> 2502606

Effect of intracerebrally injected Corynebacterium parvum on implanted brain tumor in mice.

J D Kennedy1, F K Conley.   

Abstract

Experiments were performed to determine the effectiveness of Corynebacterium parvum on resistance to growth and development of tumor in the central nervous system. A syngeneic sarcoma was injected intracerebrally into C3H/HeN/MTV-negative female mice that had received intraperitoneal injections of C. parvum or saline prior to tumor inoculation or that received intraperitoneal C. parvum or saline after tumor inoculation. Groups then received an intracerebral injection of C. parvum or saline. Our results reveal that intracerebral C. parvum elicited an intracerebral inflammatory reaction which was enhanced by prior systemic priming with C. parvum. Any inflammatory reaction which was enhanced by prior systemic priming with C. parvum. Any inflammatory reaction produced by C. parvum retarded the growth of intracerebrally-implanted sarcoma and significantly increased the survival of mice bearing such tumors. These results suggest that C. parvum may be an effective therapeutic agent in the treatment of neoplasia of the central nervous system.

Entities:  

Mesh:

Year:  1989        PMID: 2502606     DOI: 10.1007/bf00149383

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  30 in total

1.  In vitro antitumor effect of lymphoid cells from Corynebacterium parvum-treated mice: effect of route of C. parvum administration.

Authors:  A Ghaffar; R T Cullen
Journal:  J Natl Cancer Inst       Date:  1977-03       Impact factor: 13.506

2.  Effect of Corynebacterium parvum on tumor growth in the central nervous system of mice.

Authors:  F K Conley; J S Remington
Journal:  J Natl Cancer Inst       Date:  1978-09       Impact factor: 13.506

3.  Cell-mediated immunity and blocking factors in patients with tumours of the central nervous system.

Authors:  S Kumar; G Taylor; J K Steward; M A Waghe; P Morris-Jones
Journal:  Int J Cancer       Date:  1973-07-15       Impact factor: 7.396

4.  In vitro demonstration of cell-mediated immunity to human brain tumors.

Authors:  N L Levy; M S Mahaley; E D Day
Journal:  Cancer Res       Date:  1972-03       Impact factor: 12.701

5.  Tumor-specific T-lymphocyte cytotoxicity enhanced by low dose of C. parvum.

Authors:  B H Lau; R M Wang-Cheng; J Tosk
Journal:  J Leukoc Biol       Date:  1987-05       Impact factor: 4.962

6.  Interferon inducibility in mice treated with Corynebacterium parvum.

Authors:  E Storch; H Kirchner
Journal:  Antiviral Res       Date:  1985-04       Impact factor: 5.970

7.  Superiority of intralesional immunotherapy with Corynebacterium parvum and Allium sativum in control of murine transitional cell carcinoma.

Authors:  B H Lau; J L Woolley; C L Marsh; G R Barker; D H Koobs; R R Torrey
Journal:  J Urol       Date:  1986-09       Impact factor: 7.450

8.  Splenocytes from tumor-bearing Corynebacterium parvum treated mice maintain interleukin-2 and -3 activity.

Authors:  A M Roberson; K D Elgert
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

9.  Radiolabelling of Corynebacterium parvum and its distribution in mice.

Authors:  T E Sadler; W A Cramp; J E Castro
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640

10.  Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor.

Authors:  W H Brooks; M G Netsky; D E Normansell; D A Horwitz
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

View more
  2 in total

1.  Immune adjuvants for chemotherapy or radiotherapy in the 9L rat brain tumor model.

Authors:  C Liu; B F Kimler; R G Evans; R A Morantz
Journal:  J Neurooncol       Date:  1993-02       Impact factor: 4.130

Review 2.  A Janus-Faced Bacterium: Host-Beneficial and -Detrimental Roles of Cutibacterium acnes.

Authors:  Holger Brüggemann; Llanos Salar-Vidal; Harald P M Gollnick; Rolf Lood
Journal:  Front Microbiol       Date:  2021-05-31       Impact factor: 5.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.